摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-benzyl-5-hydroxypyridin-4(1H)-one | 1194473-23-8

中文名称
——
中文别名
——
英文名称
2-benzyl-5-hydroxypyridin-4(1H)-one
英文别名
2-benzyl-5-hydroxy-1H-pyridin-4-one
2-benzyl-5-hydroxypyridin-4(1H)-one化学式
CAS
1194473-23-8
化学式
C12H11NO2
mdl
——
分子量
201.225
InChiKey
JGOOWKFFSLFTFG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    49.3
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    在 5% Pd(II)/C(eggshell) 、 氢气 作用下, 以 甲醇 为溶剂, 反应 1.0h, 以115 mg的产率得到2-benzyl-5-hydroxypyridin-4(1H)-one
    参考文献:
    名称:
    Coordination Chemistry Based Approach to Lipophilic Inhibitors of 1-Deoxy-d-xylulose-5-phosphate Reductoisomerase
    摘要:
    1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) in the non-mevalonate pathway found in most bacteria is a validated anti-infective drug target. Fosmidomycin, a potent DXR inhibitor, is active against Gram-negative bacteria. A coordination chemistry and structure based approach was used to discover a novel, lipophilic DXR inhibitor with an IC50 of 1.4 mu M. It exhibited a broad spectrum of activity against Gram-negative and -positive bacteria with minimal inhibition concentrations of 20-100 mu M (or 3.7-19 mu g/mL).
    DOI:
    10.1021/jm9012592
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY<br/>[FR] NOUVEAUX INHIBITEURS DE DXR POUR THÉRAPIE ANTIMICROBIENNE
    申请人:BAYLOR COLLEGE MEDICINE
    公开号:WO2011046920A1
    公开(公告)日:2011-04-21
    The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particuarl embodiments, the compositions target DXR. In specific embodiments, the compositions are electron-deficient heterocyclic rings.
    本发明一般涉及特定的抗微生物治疗方法和组合物。在特定实施例中,这些组合物以DXR为靶点。在具体实施例中,这些组合物是电子亏缺的杂环环。
  • NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY
    申请人:Song Yongcheng
    公开号:US20130065857A1
    公开(公告)日:2013-03-14
    The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particular embodiments, the compositions target DXR. In specific embodiments, the compositions are electron-deficient heterocyclic rings.
    本发明通常涉及特定的抗微生物治疗方法和组合物。在特定实施例中,该组合物针对DXR。在具体实施例中,该组合物是电子不足的杂环环。
  • SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES
    申请人:Song Yongcheng
    公开号:US20120329842A1
    公开(公告)日:2012-12-27
    The present invention concerns methods and/or compositions for treatment and/or prevention of bacterial infection wherein the bacteria has at least one metallo-β-lactamase. The bacteria are provided with an inhibitor of the metallo-β-lactamase, for example in conjunction with an antibiotic that targets the bacteria. The bacteria may be a drug-resistant strain or susceptible to becoming a drug-resistant strain. In specific embodiments, the bacteria is Pseudomonas or Acinetobacter spp.
  • [EN] SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES<br/>[FR] COMPOSÉS À PETITES MOLÉCULES COMME INHIBITEURS À LARGE SPECTRE DE MÉTALLO-BÊTA-LACTAMASES
    申请人:BAYLOR COLLEGE MEDICINE
    公开号:WO2012088283A1
    公开(公告)日:2012-06-28
    The present invention concerns methods and/or compositions for treatment and/or prevention of bacterial infection wherein the bacteria has at least one metallo-P-lactamase. The bacteria are provided with an inhibitor of the metallo-P-lactamase, for example in conjunction with an antibiotic that targets the bacteria. The bacteria may be a drug-resistant strain or susceptible to becoming a drug-resistant strain. In specific embodiments, the bacteria is Pseudomonas or Acinetobacter spp.
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-